Topical PDT Photosensitizers (5-ALA and MAL) Therapeutic Cheat Sheet
5-aminolevulinic acid (5-ALA) is an FDA-approved prodrug used in combination with light therapy for treatment of actinic keratosis and superficial basal cell carcinoma. It is a naturally occurring amino acid that is an intermediate of the heme biosynthesis pathway which cells convert into the photosensitizing metabolite protoporphyrin IX (PpIX). This compound has been applicable in two specific cl …
5-aminolevulinic acid (5-ALA) is an FDA-approved prodrug used in combination with light therapy for treatment of actinic keratosis and superficial basal cell carcinoma. It is a naturally occurring amino acid that is an intermediate of the heme biosynthesis pathway which cells convert into the photosensitizing metabolite protoporphyrin IX (PpIX). This compound has been applicable in two specific cl … Continue reading "Topical PDT Photosensitizers (5-ALA and MAL) Therapeutic Cheat Sheet"
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in … 
Abrocitinib is an oral, once-daily selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis. It can provide rapid improvement in pruritus and skin disease and is a useful treatment option for many patients. As an oral medication, it may also be preferred by patients who want to avoid injections. When prescribing abrocitinib, it is important to discuss laboratory … 
Tranexamic acid (TXA) is a synthetic lysine derivative that reversibly blocks the lysine-binding site on plasminogen, preventing conversion to plasmin. While originally developed as an antifibrinolytic agent to reduce bleeding, TXA has several downstream effects that make it useful in dermatology, particularly for pigmentary disorders, with emerging evidence in inflammatory disorders as well. TX … 
Lebrikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets IL-13, a key cytokine implicated in the pathogenesis of type 2 inflammatory diseases.1 Lebrikizumab binds IL-13 with high affinity and a slow dissociation rate, which prevents heterodimerization of the IL-13 receptor alpha-1 subunit (IL-13Rα1) with the IL-4 receptor alpha (IL-4Rα) signaling complex. …